Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

THE TERMS OF THE 4694 and 5001 DEALS WILL BE KEY TO SHORT COVERING OR A LACK OF SHORT COVERING. MANOCEPT UPDATES WOULD ALSO BE MOST HELPFUL BUT ARE NO WHERE IN SIGHT!

The better the deal/s that the company is able to get, the more pressure the shorts will feel.

The further along Manocept is toward regulatory progess (and not just wasting money like Navidea is so good at), the more pressure the shorts will feel.

As it is, the shorts seem to be in absolutely no danger on 2/26/15.

An interesting analysis to consider is the total short covering over the most recently reported period compared to total volume for the same period. After all, our volume has been very low as of late. WHEN WE ARE SEEING HIGH SHORT COVERING WITH LOW VOLUME TRADING, THIS WILL BE A GOOD SIGN.